Clinical trial
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage…
NCT00022230 · Roger Williams Medical Center, Other · Withdrawn
Key facts
| NCT number | NCT00022230 |
|---|---|
| Title | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer |
| Official title | Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II) |
| Lead sponsor | Roger Williams Medical Center, Other |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, filgrastim, sargramostim, therapeutic autologous lymphocytes, cyclophosphamide, doxorubicin hydrochloride, paclitaxel |
| Enrollment | 0 |
| Start date | Jan 1, 2000 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | May 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: